3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
5
Thoracic
1
Plasma cell
1
Other solid neoplasm
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Dermatologic
1
Breast
1
Conditions
Melanoma
105
Skin Neoplasms
17
Neoplasm Metastasis
15
Neoplasms
10
Uveal Melanoma
9
Carcinoma, Renal Cell
9
Carcinoma, Non-Small-Cell Lung
9
Kidney Neoplasms
6
Colorectal Neoplasms
6
Carcinoma, Merkel Cell
5
Breast Neoplasms
5
Uterine Cervical Neoplasms
4
Triple Negative Breast Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
4
Ovarian Neoplasms
4
Head and Neck Neoplasms
4
Lung Neoplasms
3
Carcinoma, Transitional Cell
3
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Small Cell Lung Carcinoma
2
Sarcoma
2
Prostatic Neoplasms
2
Lymphoma
2
Eye Neoplasms
2
Carcinoma, Hepatocellular
2
Urogenital Neoplasms
1
Turcot syndrome
1
Sezary Syndrome
1
Sarcoma, Synovial
1
Interventions
pembrolizumab
18
Nivolumab
7
Cyclophosphamide
6
fludarabine
5
Docetaxel
4
atezolizumab
3
Specimen Handling
3
Paclitaxel
3
Ipilimumab
3
Gemcitabine
3
Drug Therapy
3
Carboplatin
3
Blood Specimen Collection
3
ulixertinib
2
poly ICLC
2
fludarabine phosphate
2
durvalumab
2
Standard of Care
2
Radiotherapy
2
Radiation
2
Observation
2
Magnetic Resonance Spectroscopy
2
Leucovorin
2
Filgrastim
2
Biopsy
2
zimberelimab
1
veliparib
1
trastuzumab deruxtecan
1
trastuzumab biosimilar HLX02
1
trametinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Esophageal Neoplasms
×
Interleukin-2
×
Dermatologic
×
Clear all
NCT05086692
2025-07-09
ABILITY-1
Medicenna Therapeutics, Inc.
Phase 1/2
Recruiting
115 enrolled